Clovis Oncology (CLVS)
Add to Watchlists Create an AlertCLVS Key Stats
| Income Statement | |
| Revenue TTM | 0.00 |
| Revenue Quarterly YoY Growth | |
| EPS Diluted TTM | -2.731 |
| EPS Diluted Quarterly YoY Growth | |
| Net Income TTM | -70.65M |
| Profitability | |
| Gross Profit Margin Quarterly | |
| Profit Margin Quarterly | |
| Dividend | |
| Dividend Yield | 0.00% |
| Payout Ratio TTM Pro | Go Pro |
| Current Valuation | |
| Market Cap | 872.82M |
| Enterprise Value | 728.72M |
| PE Ratio TTM | |
| PE 10 Pro | Go Pro |
| PEG Ratio | |
| Price / Book Value | 6.538 |
| Other | |
| Beta Pro | Go Pro |
| Debt to Equity Ratio | 0.00 |
| Free Cash Flow | -18.65M |
| Return on Equity | -52.72% |
CLVS News
- BioMarin Gains on Prospects for Experimental Cancer Drug May 22
- American Society Of Clinical Oncology Abstracts Point To Potential Profits May 21
- May 2013 IPO Market Update May 19
- Clovis Oncology says data to be presented at ASCO annual meeting May 16
- 10 ASCO '13 Abstracts You Can Read Right Now May 15
- 4 Stocks Rising on Unusual Volume May 8
- 4 Stocks Rising on Unusual Volume May 8
- Clovis Oncology to Present at the Bank of America Merrill Lynch 2013 Health Care... May 8
- CLOVIS ONCOLOGY, INC. Files SEC form 10-Q, Quarterly Report May 8
- Clovis Oncology's CEO Discusses Q1 2013 Results - Earnings Call Transcript Seeking Alpha May 7
CLVS Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Clovis Oncology is up 76.89% over the last year vs S&P 500 Total Return up 28.68%, Coronado Biosciences up 50.32%, and Halozyme Therapeutics down 11.48%.
CLVS Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Cash Flow Statement View Statement
You may also be interested in these CLVS related companies
Pro Ratings for CLVS
Pro Report PDF for CLVS
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.
Download CLVS Pro Report PDF
Pro Strategies Featuring CLVS
Did Clovis Oncology make it into our Pro Portfolio Strategies?
CLVS Profile
Sector: Healthcare
Industry: Biotechnology
Other CLVS Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| CLVS | 33.29 | -1.90 | -5.40% | 872.82M |
